Company / Working Capital
Cardiff Oncology, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$43.7M
FY2025
5-year range
$43.7M / $139.6M
FY2021-FY2025
Trend
-46.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 10 years, ranging from $6M in FY2017 to $140M in FY2021.
Based on SEC 10-K filings.
$44M in FY2025 with a 5-year CAGR of -19.2%.
Declined from $67M to $44M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -25.0%
- 5-Year CAGR
- -19.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -19.2%, indicating a declining trend.
- In FY2025, working capital decreased 46.4% year-over-year.
- Peak working capital was recorded in FY2021.
- Lowest working capital in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $43.7M | -46.4% |
| FY2024 | $81.6M | +21.9% |
| FY2023 | $67.0M | -35.3% |
| FY2022 | $103.5M | -25.9% |
| FY2021 | $139.6M | +9.7% |
| FY2020 | $127.2M | +1836.1% |
| FY2019 | $6.6M | -32.9% |
| FY2018 | $9.8M | +77.4% |
| FY2017 | $5.5M | -82.3% |
| FY2016 | $31.2M | -48.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026